Abstract
Oxaceprol, a derivative of l-proline, is an established drug for managing osteoarthritis (OA) with better safety profile than non-steroidal anti-inflammatory drugs (NSAIDs). This systematic review and meta-analysis, following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, evaluated the efficacy, safety and tolerability of oxaceprol in OA. Electronic databases for published and grey (unpublished) literature were searched to identify parallel-group randomized controlled trials (RCTs) evaluating the impact of oxaceprol in patients with OA. Risk of bias was assessed using the Cochrane collaboration’s tool. A total of seven parallel-group RCTs involving 1087 participants were included in the systematic review. Meta-analysis, in Review Manager, demonstrated numerically greater/significant improvements compared to active control [diclofenac/ibuprofen]/placebo in pain and function of joint; similar improvement vs. active control in global treatment efficacy; no difference/significant difference vs. active control/placebo in NSAIDs as rescue medication. Treatment with oxaceprol showed numerically less adverse events (AEs) than active control (diclofenac: risk ratio [RR], 0.71; 95% confidence interval [CI], 0.45 to 1.11; p = 0.14: ibuprofen: RR, 0.73; 95% CI, 0.30 to 1.78; p = 0.49) and significantly fewer AEs compared to placebo (RR, 0.76; 95% CI, 0.63 to 0.92; p = 0.004). Given the nature of small-to-moderate sample size and short duration of eligible studies, the available clinical evidence of oxaceprol in the management of OA is modest — though looks promising. New and better RCTs with larger sample size and longer follow-up are warranted to strengthen the use of oxaceprol in clinical setting for managing OA.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
WHO Chronic rheumatic conditions. WHO n.d. https://doi.org/www.who.int/chp/topics/rheumatic/en/ (accessed June 2, 2018).
Arthritis by the Numbers | Scientific Research | Arthritis Foundation. ArthritisOrg n.d. https://doi.org/www.arthritis.org/arthritis-cure/scientific-facts/(accessed June 2, 2018).
Johnson VL, Hunter DJ. The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol 2014;28:5–15, doi:https://doi.org/10.1016/j.berh.2014.01.004.
Nüesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Jüni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011;342:d1165, doi:https://doi.org/10.1136/bmj.d1165.
Maiese K. Picking a bone with WISP1 (CCN4): new strategies against degenerative joint disease. J Transl Sci 2016;1:83–5.
Sinusas K. Osteoarthritis: diagnosis and treatment. Am Fam Phys 2012;85:49–56.
Yusuf E. Pharmacologic and non-pharmacologic treatment of osteoarthritis. Curr Treat Options Rheum 2016;2:111–25, doi:https://doi.org/10.1007/s40674-016-0042-y.
Gore M, Tai K-S, Sadosky A, Leslie D, Stacey BR. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. Pain Pract 2012;12:550–60, doi:https://doi.org/10.1111/j.1533-2500.2012.00532.x.
Jüni P, Reichenbach S, Dieppe P. Osteoarthritis: rational approach to treating the individual. Best Pract Res Clin Rheumatol 2006;20:721–40, doi:https://doi.org/10.1016/j.berh.2006.05.002.
da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2017;390: e21–33, doi:https://doi.org/10.1016/S0140-6736(17)31744-0.
Alacqua M, Trifirò G, Cavagna L, Caporali R, Montecucco CM, Moretti S, et al. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. Arthritis Rheum 2008;59:568–74, doi:https://doi.org/10.1002/art.23526.
Lapane KL, Liu S-H, Dubé CE, Driban JB, McAlindon TE, Eaton CB. Factors associated with the use of hyaluronic acid and corticosteroid injections among patients with radiographically confirmed knee osteoarthritis: a retrospective data analysis. Clin Ther 2017;39:347–58, doi:https://doi.org/10.1016/j.clinthera.2017.01.006.
Park H-R, Cho S-K, Im SG, Jung S-Y, Kim D, Jang EJ, et al. Treatment patterns of knee osteoarthritis patients in Korea. Korean J Intern Med 2018, doi:https://doi.org/10.3904/kjim.2017.304.
Ullal SD, Sanji N, Kamath RK, Pai M, Kamath SU, Savur AD. Prescribing pattern for osteoarthritis in a tertiary care hospital. J Clin Diagn Res 2010;4:2421–6.
Wilson N, Sanchez-Riera L, Morros R, Diez-Perez A, Javaid MK, Cooper C, et al. Drug utilization in patients with OA: a population-based study. Rheumatology (Oxford) 2015;54:860–7, doi:https://doi.org/10.1093/rheumatology/keu403.
Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017;357:, doi:https://doi.org/10.1136/bmj.j1909.
Dib RA, Chinzon D, de S Fontes LH, de Sá Teixeira AC, Navarro-Rodriguez T. Ulcer and bleeding complications and their relationship with dyspeptic symptoms in NSAIDs users: a transversal multicenter study. Scand J Gastroenterol 2014;49:785–9, doi:https://doi.org/10.3109/00365521.2014.919016.
García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52:1628–36, doi:https://doi.org/10.1016/j.jacc.2008.08.041.
Lanas A, Garcia-Tell G, Armada B, Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med 2011;9:38, doi:https://doi.org/10.1186/1741-7015-9-38.
Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002;89:204–9, doi:https://doi.org/10.1016/S0002-9149(01)02201-9.
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247–55, doi:https://doi.org/10.1001/jama.284.10.1247.
Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165:161–8, doi:https://doi.org/10.1001/archinte.165.2.161.
Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086, doi:https://doi.org/10.1136/bmj.c7086.
Walter RB, Milano F, Brasky TM, White E. Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. J Clin Oncol 2011;29:2424–31, doi:https://doi.org/10.1200/JCO.2011.34.6346.
Parnham MJ. Antirheumatic agents and leukocyte recruitment. New light on the mechanism of action of oxaceprol. Biochem Pharmacol 1999;58:209–15, doi:https://doi.org/10.1016/S0006-2952(99)00056-8.
Ionac M, Parnham MJ, Plauchithiu M, Brune K. Oxaceprol, an atypical inhibitor of inflammation and joint damage. Pharmacol Res 1996;33:367–73, doi:https://doi.org/10.1006/phrs.1996.0051.
Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs 1996;52(Suppl. 5):13–23, doi:https://doi.org/10.2165/00003495-199600525-00004.
Bauer HW, Klasser M, von Hanstein KL, Rolinger H, Schladitz G, Henke HD, et al. Oxaceprol is as effective as diclofenac in the therapy of osteoarthritis of the knee and hip. Clin Rheumatol 1999;18:4–9, doi:https://doi.org/10.1007/s100670050043.
Herrmann G, Steeger D, Klasser M, Wirbitzky J, Fürst M, Venbrocks R, et al. Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac. Clin Rheumatol 2000;19:99–104, doi:https://doi.org/10.1007/s100670050025.
Hildebrandt H. Therapie von gon- und coxarthrosen. Klinischer vergleich von oxaceprol und ibuprofen [Therapy of gonarthrosis and coxarthrosis. Clinical comparison of oxaceprol and ibuprofen]. Zeitschrift Fur Allgemeinmedizin 1995;71: 1742–1744+1747–1748.
Steinbach K, Bauer HW. Klinischer Vergleich von Oxaceprol und Diclofenac bei Gon-und Koxarthrosen [Clinical comparison of oxaceprol and diclofenac in gonarthrosis and coxarthrosis]. Extracta Orthop 1995;18:18–21.
Vagt CW, Kaiser T, Leineweber G. Wirksamkeitsvergleich der oralen Therapie mit Oxazeprol versus Ibuprofen bei Gonarthrose und Coxarthrose [Efficacy comparison of oral therapy with oxaceprol versus ibuprofen in gonarthrosis and coxarthrosis]. Rheuma 1990;10:263–7.
Pawar HS, Francis NK, Hota T, Peter N, Mitra A. Comparative evaluation of therapeutic efficacy of intra-articular oxaceprol with conventional modalities in osteoarthritis animal model. Clin Rheumatol 2018;37:2195–201, doi:https://doi.org/10.1007/s10067-018-4087-1.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100, doi:https://doi.org/10.1371/journal.pmed.1000100.
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928, doi:https://doi.org/10.1136/bmj.d5928.
Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Wiley Online Library; 2008, doi:https://doi.org/10.1002/9780470712184.
Michael B, Larry VH, Julian H, Hannah RW. Introduction to meta-analysis. UK: A John Wiley and Sons Ltd; 2009, doi:https://doi.org/10.1002/9780470743386.
Feldman S, Bergal S, Nores JM, Dalayeun JF, Remy J. Traitement par la N-acétyl-hydroxyproline des arthropathies dégénératives: analyse et synthèse de 7 essais cliniques [Treatment of degenerative osteoarticular disease with N-acetyl-hydroxyproline. Analysis and synthesis of 7 clinical trials]. Rhumatologie 1994;46: 281–281.
Juvin E. Essai pragmatique de l’oxacéprol 200 mg dans le traitement au long cours de l’arthrose des membres inférieurs [A pragmatic trial of oxaceprol 200 mg in the long-term treatment of lower limb osteoarthritis]. Semaine Des Hopitaux de Paris 1998;74:47–54.
Krüger K, Klasser M, Mössinger J, Becker U. Oxaceprol-a randomised, placebo-controlled clinical study in osteoarthritis with a non-conventional nonsteroidal anti-inflammatory drug. Clin Exp Rheumatol 2007;25:29–34.
A phase III, multicentric, single blind, randomized, comparative study to assess the efficacy and safety of Oxaceprol capsule with Diclofenac tablet in patients with osteoarthritis [CTRI/2009/091/000798]. n.d. https://doi.org/www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=968 (accessed June 12, 2018).
Oxaceprol versus tramadol in knee osteoarthritis: a randomized controlled trial [CTRI/2014/08/004821]. n.d. https://doi.org/www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=7458 (accessed June 12, 2018).
Diehl K, Fallot-Burghardt W, Frie A. Die Therapie der Gonarthrose mit Oxaceprol [The Therapy of gonarthrosis with Oxaceprol] 1985;35:. p. 51–7.
Diehl K, Fallot-Burghardt W, Frie A. Treatment of patella chondropathy with oxaceprol. Therapiewoche 1985;35:3388–92.
Finkbeiner G. Konservative Behandlung der Gonarthrose mit oxaceprol. Therapiewoche 1986;36:116–9.
Franz M. Die Behandlung degenerativer Gelenkerkrankungen mit Oxaceprol. Rheuma 1992;12:137–41.
Laborie G, Arramon JY. [The acetyl-hydroxyproline, metabolic harmonizator of connective tissue (100 cases in rheumatologic practice)]. Bord Med 1970;3:3059–60 passim.
Michael J. Die Therapie von Koxarthrosen und Gonarthrosen mit Oxaceprol [Therapy of coxarthrosis and gonarthrosis with Oxaceprol]. Therapiewoche 1986;36:3076–81.
Schubotz R, Hausmann L. Behandlung degenerative Gelenkerkrankungen mit N-Acetyl-Hydroxyprolin [Treatment of degenerative joint disease with N-acetyl-hydroxyproline]. Therapiewoche 1977;27:4248–52.
NDI 176 — N-Acetyl-L-Hydroxyproline — Supporting & Related Materials n.d. https://doi.org/www.regulations.gov/document?D=FDA-2004-S-0571-0026 (accessed November 10, 2018).
Sites BD, Masaracchia MM, Davis M. Distinguishing between efficacy and real-world effectiveness: the case for thinking beyond classic randomized controlled trial design. Reg Anesth Pain Med 2017;42:131–2, doi:https://doi.org/10.1097/AAP.0000000000000563.
Gurevitch J, Koricheva J, Nakagawa S, Stewart G. Meta-analysis and the science of research synthesis. Nature 2018;555:175–82, doi:https://doi.org/10.1038/nature25753.
Barton S. Which clinical studies provide the best evidence? The best RCT still trumps the best observational study. BMJ 2000;321:255–6, doi:https://doi.org/10.1136/bmj.321.7256.255.
Oxford Centre for Evidence-based Medicine — Levels of Evidence (March 2009). CEBM 2009. https://doi.org/www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ (accessed July 19, 2018).
Witte S, Lasek R, Victor N. Wirksamkeit von Ademetionin und Oxaceprol für die Behandlung von Arthrosen [Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritis]. Orthopade 2002;31:1058–65, doi:https://doi.org/10.1007/s00132-002-0366-1.
Brune K, Graf P, Glatt M. Inhibition of prostaglandin synthesis in vivo by nonsteroid anti-inflammatory drugs: evidence for the importance of pharmacokinetics. Agents Actions 1976;6:159–64, doi:https://doi.org/10.1007/BF01972201.
Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974;26:33–67.
Clayton JJ. Nutraceuticals in the management of osteoarthritis. Orthopedics 2007;30:624–9, doi:https://doi.org/10.3928/01477447-20070801-13 quiz 630-1.
Ragle RL, Sawitzke AD. Nutraceuticals in the management of osteoarthritis: a critical review. Drugs Aging 2012;29:717–31, doi:https://doi.org/10.1007/s40266-012-0006-3.
Veihelmann A, Hofbauer A, Refior HJ, Messmer K. Oxaceprol, an atypical inhibitor of inflammation, reduces leukocyte adherence in mouse antigen-induced arthritis. Acta Orthop Scand 2001;72:293–8, doi:https://doi.org/10.1080/00016470152846655.
Harris A, Schropp A, Messmer K. Effects of oxaceprol on the microcirculation in ischemia/reperfusion injury. Eur J Med Res 1998;3:182–8.
Walker-Bone K, Javaid K, Arden N, Cooper C. Regular review: medical management of osteoarthritis. BMJ 2000;321:936–40, doi:https://doi.org/10.1136/bmj.321.7266.936.
Samant AP, Samant PD, Nayak UV. Comparative study of therapeutic efficacy and safety of oxaceprol and oral glucosamine in patients with osteoarthritis of knee. Indian J Pharmacol 2013;45: S111–S111.
Author information
Authors and Affiliations
Corresponding author
Supplementary data
Rights and permissions
About this article
Cite this article
Durg, S., Lobo, M., Venkatachalam, L. et al. A systematic review and meta-analysis of oxaceprol in the management of osteoarthritis: An evidence from randomized parallel-group controlled trials. Pharmacol. Rep 71, 374–383 (2019). https://doi.org/10.1016/j.pharep.2018.12.010
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2018.12.010